Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported FCF Margin over the past 12 years, most recently at 18177.27% for Q4 2025.

  • Quarterly results put FCF Margin at 18177.27% for Q4 2025, up 8383106.0% from a year ago — trailing twelve months through Dec 2025 was 390.81% (up 7670522.0% YoY), and the annual figure for FY2025 was 390.81%, up 7670522.0%.
  • FCF Margin for Q4 2025 was 18177.27% at Viridian Therapeutics, Inc.\DE, down from 120.08% in the prior quarter.
  • Over the last five years, FCF Margin for VRDN hit a ceiling of 120.08% in Q3 2025 and a floor of 128804.17% in Q1 2025.
  • Median FCF Margin over the past 5 years was 43191.31% (2023), compared with a mean of 42841.19%.
  • Peak annual rise in FCF Margin hit 8383106bps in 2025, while the deepest fall reached -6599444bps in 2025.
  • Viridian Therapeutics, Inc.\DE's FCF Margin stood at 7765.89% in 2021, then tumbled by -320bps to 32640.95% in 2022, then tumbled by -65bps to 53990.28% in 2023, then crashed by -89bps to 102008.33% in 2024, then surged by 82bps to 18177.27% in 2025.
  • The last three reported values for FCF Margin were 18177.27% (Q4 2025), 120.08% (Q3 2025), and 100553.33% (Q2 2025) per Business Quant data.